Who are Rifampin/isoniazid FDC's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rifampin-isoniazid-fdc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rifampin/isoniazid FDC — Competitive Intelligence Brief

Rifampin/isoniazid FDC (Rifampin/isoniazid FDC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antituberculous agent (fixed-dose combination). Area: Infectious Disease.

marketed Antituberculous agent (fixed-dose combination) Bacterial RNA polymerase (rifampin); mycolic acid biosynthesis (isoniazid) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Rifampin/isoniazid FDC (Rifampin/isoniazid FDC) — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Rifampin and isoniazid are bactericidal antibiotics that inhibit bacterial RNA polymerase and mycolic acid synthesis, respectively, to kill Mycobacterium tuberculosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifampin/isoniazid FDC TARGET	Rifampin/isoniazid FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antituberculous agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin); mycolic acid biosynthesis (isoniazid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antituberculous agent (fixed-dose combination) class)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rifampin/isoniazid FDC — Competitive Intelligence Brief. https://druglandscape.com/ci/rifampin-isoniazid-fdc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab